Physician profile
Henry Watson
NPI 1235142894
$2,204.42
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $264 · 2021: $311 · 2022: $656 · 2023: $399 · 2024: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.13 | 2021-2024 | Creon, Mavyret, Ubrelvy |
| Collegium Pharmaceutical, INC. | $280.91 | 2022-2024 | Belbuca, Xtampza |
| Astrazeneca Pharmaceuticals Lp | $250.85 | 2019-2023 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.58 | 2019-2022 | |
| Novo Nordisk INC | $178.53 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $161.12 | 2022-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $92.44 | 2019-2022 | |
| Lundbeck LLC | $75.40 | 2022 | |
| Janssen Pharmaceuticals, INC | $67.21 | 2019 | |
| Pfizer INC. | $51.28 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.88 | 2020-2021 | |
| Amgen INC. | $31.43 | 2024 | Repatha, Otezla |
| Lilly USA, LLC | $26.08 | 2023 | Amyvid |
| Allergan, INC. | $24.72 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.67 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $24.02 | 2022 | |
| Ucb, INC. | $23.50 | 2019 | |
| Medtronic, INC. | $20.65 | 2021 | |
| Merck Sharp & Dohme LLC | $17.63 | 2023 | Verquvo, Belsomra |
| Arbor Pharmaceuticals, INC. | $17.15 | 2019 | |
| Medtronic Minimed, INC. | $13.24 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.